Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at Wedbush

Bicara Therapeutics (NASDAQ:BCAX) was upgraded by equities research analysts at Wedbush to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

BCAX has been the topic of several other research reports. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating on the stock. Morgan Stanley initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price target for the company. HC Wainwright lifted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Finally, Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Price Performance

BCAX stock opened at $12.60 on Wednesday. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The stock has a 50-day simple moving average of $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds have recently made changes to their positions in the business. First Turn Management LLC bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at about $14,324,000. Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $1,239,000. Vestal Point Capital LP bought a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $10,825,000. FMR LLC bought a new stake in Bicara Therapeutics in the third quarter worth $57,913,000. Finally, Braidwell LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at about $42,219,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.